Advertisement

(http://www.hansenmedical.com)

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible

robotics and the developer of robotic technology for accurate 3D

control of catheter movement, today announced it will showcase its

Magellan Robotic System at the 34th Annual Charing Cross

International Symposium from April 14-17 in London.

Hansen Medical will also be exhibiting its NorthStar Robotic

Catheter, designed to work with the Magellan Robotic System. The

NorthStar Catheter is designed to simplify and enhance catheter

navigation and therapeutic intervention through a variety of clinical

cases in the peripheral vasculature. The Magellan Robotic System and

NorthStar Robotic Catheter are CE marked and available for sale in

Europe.

The Company will be conducting product demonstrations and exhibiting

the Magellan Robotic System and NorthStar Robotic Catheter at Booth

409.

"We are excited to showcase our Magellan Robotic System and NorthStar

Robotic Catheter at Charing Cross, a key conference of vascular

surgeons, as we believe these exciting new products have the potential

to enhance the way physicians navigate the vasculature based on the

initial clinical and pre-clinical work and feedback from a number of

leading clinicians worldwide," said Bruce Barclay, president and CEO

of Hansen Medical. "The system and catheter give physicians maximum

flexibility and control through independent distal tip control of a

catheter and a sheath as well as through robotic manipulation of a

standard guidewire from a centralized, remote workstation. Moreover,

this proprietary technology is designed to deliver predictable

catheter navigation of peripheral vessels."

In addition, the Company will be sponsoring a Lunch Symposium hosted

jointly with Philips Healthcare, from 1:10pm-2:10pm on Sunday, April

15, in the Blue Learning Center. During this Symposium, Professor

Jean-Paul de Vries, M.D., PhD., of St. Antonius Hospital in

Nieuwegein, The Netherlands, Professor Jean-Pierre Becquemin, M.D., of

Henri Mondor Hospital in Creteil, France, Dr. Jean Bismuth, M.D., of

the DeBakey Heart & Vascular Center, Methodist Hospital in Houston,

and Professor Nick Cheshire, M.D., of St. Mary's Hospital, part of the

Imperial College Healthcare NHS Trust, in London, UK, will present on

new frontiers in hybrid operating rooms, advanced imaging, and

endovascular robotics.

"We are very pleased to host a Symposium with our partner Philips.

This Symposium reflects our strong relationship with a global leader

in medical imaging, and emphasizes the potential of combining advanced

imaging with our flexible robotic catheter platform to deliver

state-of-the-art solutions to our customers," concluded Barclay.

In addition, Dr. Celia Riga, M.D., of St. Mary's Hospital, part of the

Imperial College Healthcare NHS Trust, in London, will give a

presentation on Hansen Medical's flexible robotic catheters in the CX

Innovation Showcase session, at 12:05pm on Monday, April 16.

The Magellan Robotic System and NorthStar Robotic Catheter are

intended to be used to facilitate navigation to anatomical targets in

the peripheral vasculature and subsequently provide a conduit for

manual placement of therapeutic devices.

About the Magellan Robotic SystemHansen Medical's Magellan Robotic

System is based upon the flexible robotic technology incorporated in

the Sensei-X@ Robotic Catheter System currently sold in the U.S. and

Europe, which has been used in over 7,000 patients with cardiac

arrhythmia, but includes a number of key enhancements. In particular,

the Magellan Robotic System:

In 2010, the Company announced the completion of its First-in-Man

study in Europe during which 20 endovascular procedures were

successfully performed with an earlier version of the Magellan Robotic

System, demonstrating its potential to allow physicians to effectively

treat peripheral vascular disease, while lessening radiation exposure.

In Europe, the Magellan Robotic System, including the NorthStar

Robotic Catheter and related accessories, are CE marked. In the U.S.,

the Magellan Robotic System requires U.S. Food & Drug Administration

(FDA) clearance, and a 510(k) application is currently pending. As

such, the products are not commercially available in the U.S.

About Hansen Medical, Inc. Hansen Medical, Inc., based in Mountain

View, California, develops products and technology using robotics for

the accurate positioning, manipulation and control of catheters and

catheter-based technologies. The Company's Sensei@ X Robotic Catheter

System and Artisan Control Catheter were cleared by the U.S. Food and

Drug Administration for manipulation and control of certain mapping

catheters in electrophysiology (EP) procedures. This robotic catheter

system is compatible with fluoroscopy, ultrasound, 3D surface map and

patient electrocardiogram data. In the United States, the Sensei

System is not approved for use in guiding ablation procedures; this

use remains experimental and is currently under investigation in a

multi-center IDE study. The U.S. product labeling provides that the

safety and effectiveness of the Sensei X System and Artisan Control

Catheter for use with cardiac ablation catheters in the treatment of

cardiac arrhythmias, including atrial fibrillation (AF), have not been

established. In the European Union, the Sensei X System and Artisan

Control Catheter are cleared for use during EP procedures, such as

guiding catheters in the treatment of AF, and the Lynx@ Robotic

Ablation Catheter is cleared for the treatment of AF. The Company's

Magellan Robotic System, NorthStar Robotic Catheter and related

accessories, which are intended to facilitate navigation to anatomical

targets in the peripheral vasculature and subsequently provide a

conduit for manual placement of therapeutic devices, have undergone

conformity assessment and CE marking and are commercially available in

the European Union.

In the U.S., the Magellan Robotic System, the NorthStar Robotic

Catheter and accessories are the subject of a current filing with the

FDA and are not commercially available. Additional information can be

found at

www.hansenmedical.com(http://ctt.marketwire.com/?release872158&id1467913&type1&urlhttp%3a%2f%2fwww.hansenmedical.com%2f).

Forward-Looking StatementsThis press release contains forward-looking

statements regarding, among other things, statements relating to

goals, plans, expectations, objectives, milestones and future events.

All statements, other than statements of historical fact, are

statements that could be deemed forward-looking statements, including

statements containing the words "plan," "expects," "potential,"

"believes," "goal," "estimate," "anticipates", and similar words.

These statements are based on the current estimates and assumptions of

our management as of the date of this press release and are subject to

risks, uncertainties, changes in circumstances and other factors that

may cause actual results to differ materially from the information

expressed or implied by forward-looking statements made in this press

release. Examples of such statements include statements about the

anticipated growth of Hansen's flexible robotic technology in both EP

and vascular applications and statements about the anticipated timing

of regulatory clearances, including 510(k) clearance in the United

States. Important factors that could cause actual results to differ

materially from those indicated by such forward-looking statements

include, among others: engineering, regulatory and sales challenges in

developing new products and entering new markets; potential safety and

regulatory issues that could slow or suspend our sales; the uncertain

timelines, costs and results of pre-clinical and clinical trials; the

rate of adoption of our systems and the rate of use of our catheters;

the scope and validity of intellectual property rights applicable to

our products; competition from other companies; our ability to recruit

and retain key personnel; our ability to maintain our remedial actions

over previously reported material weaknesses in internal controls over

financial reporting; the effect of credit, financial and economic

conditions on capital spending by our potential customers; our ability

to manage expenses and obtain additional financing; and other risks

more fully described in the "Risk Factors" section of our Annual

Report on Form 10-K for the year ended December 31, 2011 filed with

the SEC on March 15, 2012 and the risks discussed in our other reports

filed with the SEC. Given these uncertainties, you should not place

undue reliance on the forward-looking statements in this press

release. We undertake no obligation to revise or update information

herein to reflect events or circumstances in the future, even if new

information becomes available.

Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart

Design), and Sensei are registered trademarks of Hansen Medical, Inc.

in the United States and other countries.

Advertisement
Advertisement